Abstract
INTRODUCTION
Acute kidney injury (AKI), including hepatorenal syn drome (HRS), is a common complication of patients with acuteonchronic liver failure (ACLF) or decompensated cirrhosis (DC) and is always associated with poor outcome [13] . Previous studies have clearly demonstrated that acuteonchronic liver failure and decompensated cirrhosis are two different diseases [4, 5] . In patients with decompensated cirrhosis, the liver and extrahepatic organ failure usually occurs gradually over several weeks to several months on the basis of cirrhosis, and patients often have severe circulatory dysfunction. For acuteonchronic liver failure, the liver failure often happens suddenly within 4 wk, in patients with either previously diagnosed or undiagnosed chronic liver disease and is usually associated with a precipitating even, and the systemic inflammatory response play an important role in the pathogenesis of organ failure [4, 5] . However, the differences in acute kidney injury between patients with these two diseases are rarely studied, and it is uncertain whether AKI should be treated in the same way in these two diseases. A clear clarification on the differences in AKI between ACLF and DC patients will promote timely and more appropriate management of the patients.
Clinically, AKI can be divided into structural and functional kidney injury, prerenal azotemia and HRS are the most common causes of functional kidney injury, and acute tubular necrosis is the most common cause of structural renal impairment [68] . Accurate distinguishing the etiologies of AKI is critical as their treatments differ markedly [68] . In recent years, studies on kidney tubular injury biomarkers for early detection of AKI have garnered broad interest, several studies demonstrated that some of these biomarkers in urine are significantly increased in patients with structural kidney injury and have the potential to distinguish structural from functional AKI, the combination of these biomarkers can improve the accuracy of diagnosis [710] . Terlipressin is a vasoconstrictor and is widely used in the treatment of HRS. Previous studies have shown that it can improve renal function in most patients with HRS.However, it is ineffective in patients with structural kidney injury [11, 12] . Furthermore, due to the high incidence of hepatitis B virus (HBV) infection, patients with HBVACLF account for over 80% of all ACLF patients in China [1] . Therefore, in this prospective study, we assessed the levels of five extensively studied urinary biomarkers of tubular damage, including neutrophil gelatinaseassociated lipocalin (NGAL), interleukin18 (IL18), kidney injury molecule1 (KIM1), livertype fatty acid binding protein (LFABP), and cystatin C (CysC), to explore the etiological differences of AKI between HBVACLF and HBVDC patients. Simultaneously, differences in the natural course of AKI, patient's response to terlipressin treatment and patient outcomes were also evaluated, aimed to clarify the differences in AKI between ACLF and DC patients.
MATERIALS AND METHODS

Patients
Consecutive patients with HBVACLF or HBVDC who were admitted to Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology between December 2015 and July 2017 were enrolled in this observational study. This study was approved by the Ethics Committee of Tongji Hospital (TJC20151108), and written informed consents were obtained from all participants or their legal representatives. Two hundred and eighty patients with HBVACLF and 132 patients with HBVDC were recruited and were divided into four groups according to the presence of ACLF, DC, and AKI, as follows: (1) Patients with DC without AKI (DCnonAKI) group; (2) patients with ACLF without AKI (ACLFnon AKI) group; (3) patients with both DC and AKI (DCAKI) group; and (4) patients with both ACLF and AKI (ACLFAKI) group. Patients with HBVACLF were diagnosed according to the definition of the AsianPacific Association for the Study of the Liver (APASL) 2014 [5] , this includes patients with previous HBV infection who had developed jaundice (total bilirubin ≥ 5 mg/dL) and coagulopathy (prothrombin activity (PTA) < 40% or INR ≥ 1.5) within 4 wk, and complicated by ascites and/or encephalopathy. HBVDC patients were those with HBVrelated cirrhosis, which were confirmed by a combination of clinical, imaging (computed tomography, magnetic resonance imaging, or ultrasonography) and endoscopic findings, presenting with significant signs of decompensation, such as ascites, hepatic encephalopathy, variceal bleeding, spontaneous bacterial peritonitis (SBP), or hepatorenal syndrome, but have not yet reached the ACLF diagnostic criteria, or have a history of liver function decompensation [13] . AKI was diagnosed according to the International Club of Ascites (ICA)AKI criteria [3] , as follows: an increase in serum creatinine by more than 0.3 mg/dL (≥ 26.5 µmol/L) within 48 h or to more than 1.5 times the baseline value. The most recent serum creatinine result within the previous three months, or the serum creatinine result upon hospital admission, was considered as the baseline serum creatinine. AKI was categorized into three stages according to the ICAAKI staging standard [3] : Stage 1 (AKI1), an increase in serum creatinine to more than 0.3 mg/dL (26.5 µmol/L) or by 1.5 to 2 fold from baseline value; stage 2 (AKI2), an increase in serum creatinine by 2 to 3 fold from baseline value; stage 3 (AKI3), an increase in serum creatinine to more than 3 fold from baseline or need renal replacement therapy. The recovery or progression of AKI was evaluated at discharge and the patients were classified as nochange (if there was no change of AKI stage), recovery (if the patient reached a lower stage from the first recorded or acquired a normal renal function), or progression (if there was AKI stage deterioration to a higher stage or if the patient needed dialysis).
Twentyfour patients with mild chronic hepatitis B (CHB) and 20 health controls (HC) during the same period were also included as control groups. Our exclusion criteria included those patients with chronic kidney disease, obstructive uropathy, urinary tract infection, hepatocellular carcinoma or other malignancies, cirrhosis or liver failure without HBV infection, acute liver failure, previous kidney or liver transplantation, pregnancy, age < 18 or > 80 years.
All study participants were hospitalized and received antiHBV therapy along with standard supportive treat ment according to their individual indications. Patients with stage 2 or 3 AKI who do not respond to the diuretic withdrawal and plasma volume expansion with albumin and without apparent structural kidney injury had received terlipressin treatment according to the International Club of Ascites (ICA)AKI recommendations [3] . Among them, 10 patients with ACLFAKI and 6 patients with DCAKI were treated with octreotide at the same time due to gastrointestinal bleeding or acute pancreatitis. Patient' s response to terlipressin was assessed at the end of treatment, as follows: (1) No response, no regression of AKI; (2) partial response, AKI regression to a lower stage with serum creatinine decreased to ≥ 0.3 mg/dL (26.5 µmol/L) above the baseline value; or (3) full response, serum creatinine decreased to a value within 0.3 mg/dL (26.5 µmol/L) of the baseline value.
Patient demographics, clinical and laboratory data,and the natural course of AKI were recorded after enrollment, all patients were followed up for at least 3 mo or until death.
Specimen collection and biomarker measurement
Ten milliliter of fresh urine samples were collected on the day of enrollment and/or after AKI was confirmed. The samples were immediately centrifuged at 3000 rpm for 15 min at 4 ℃ and the supernatants were subsequently stored at -80 ℃ for future biomarker and creatinine measurements. Five urine samples were could not be collected due to either the patients' inability to cooperate or the presence of anuria. Samples from 24 CHB patients and 20 healthy controls (HC) were also collected.
The biomarkers of kidney tubular damage were measured using corresponding enzymelinked immuno sorbent assay (ELISA) kits according to the manufacturers' instructions: NGAL (BioPorto, Gentofte, Denmark), LFABP (Hycultbiotech, Uden, The Netherlands), IL18 (Medical and Biological Laboratories, Nagoya, Japan), CysC (R&D Systems, Minneapolis, MN), KIM1 (R&D Systems, Minneapolis, MN).The ELISA methods and detection ranges for these biomarkers were as previously described [14, 15] . All intraassay and interassay variabilities were less than 10%. Urine creatinine was measured by enzyme colorimetry using an automatic biochemical analyzer (cobas8000, Roche Diagnostics, Mannheim, Germany).The concentrations of all urinary biomarkers were normalized to urinary creatinine to adjust for variations of urine concentration.
Statistical analysis
In this study, categorical variables were expressed as HBVDC were enrolled. During admission or hospi talization, 71 and 28 patients developed AKI in HBV ACLF and HBVDC groups, respectively (25.4% vs 21.2%, P = 0.358). Baseline and hospitalization characteristics of patients with HBVACLF or HBVDC are shown in Tables 1 and 2 .
Patients in the ACLFAKI group had the highest Model for Endstage Liver Disease (MELD) score, serum bilirubin levels, INR, and leukocyte counts and the lowest serum sodium levels. In contrast, patients with DCAKI had the lowest serum albumin and hemoglobin levels. Prevalences of ascites, SBP, and pulmonary infection was noted to be higher among AKI patients compared to those without AKI, but there were no differences between the ACLFAKI and DCAKI groups. Hepatic encephalopathy (HE) was more common in ACLFAKI patients than in DCAKI patients.
The levels of tubular damage biomarkers
The concentrations of NGAL, CysC, LFABP, IL18 in urine were found to be significantly elevated in patients frequencies and percentages, and were compared using Fisher's exact test or the chi-square test. Continuous variables were reported as mean ± SD for normally distributed variables and were compared using the Student's t test or oneway ANOVA testing. Continuous variables with nonnormal distributions were presented as medians with interquartile ranges (IQR) and were compared using the MannWhitney U test or the Kruskall Wallis test. The cumulative survival rates at 90 d were estimated using the KaplanMeier method and were compared by the Logrank test. A Cox proportional hazards model, adjusted for potential confounders, was used to estimate the effects of DC, ACLF and AKI on 90day mortality. All analyses in this study were conducted using IBM SPSS Statistics 23.0 and P < 0.05 (two-sided) was considered statistically significant.
RESULTS
Patient's characteristics and demographics
A total of 280 patients with HBVACLF and 132 with with ACLFAKI, which were markedly higher than those in the DCAKI group and the groups without AKI,but there was no significant difference in the levels of these biomarkers between DCAKI and nonAKI patients. The level of urinary KIM1 was significantly higher in ACLFAKI patients than in those without AKI, while no difference was observed between ACLFAKI and DCAKI groups (Figure 1 ).
Recovery and progression of AKI
At the time of AKI diagnosis, there were 33 (46.5%) AKI1, 28 (39.4%) AKI2, and 10 (14.1%) AKI3 patients in the ACLFAKI group and 17 (60.7%) AKI1, 9 (32.1%) AKI2, and 2 (7.2%) AKI3 patients in the DCAKI group (P = 0.396) (Figure 2A ). However, for the peak stages of AKI, these proportions were significantly different among ACLFAKI and DCAKI patients: there were 23 (32.4%) AKI1, 22 (31%) AKI2, and 26 (36.6%) AKI3 patients in the ACLFAKI group and 13 (46.4%) AKI1, 12 (42.9%) AKI2, and 3 (10.7%) AKI3 patients in the DCAKI group (P = 0.039) ( Figure  2B ). Next, we assessed the progression of AKI at discharge and found a higher proportion of patients with AKI progression in the ACLFAKI group than in the DC AKI group (49.3% vs 17.9%, P = 0.013) ( Figure 2C ).
Patients' response to terlipressin treatment
There were 43 and 19 patients treated with terlipressin in the ACLFAKI and DCAKI groups, respectively (60.6% vs 67.9%, P = 0.499). At the end of treatment, there were 27 (62.8%) nonresponders, 2 (4.7%) partial responders, and 14 (32.6%) full responders in the ACLFAKI group and 5 (26.3%) nonresponders, 3 (15.8%) partial responders, and 11 (57.9%) full responders in the DCAKI group. The response rate in the ACLF-AKI group was significantly lower than that in the DCAKI group (P = 0.018) ( Figure 2D ). Next, we used logistic regression analysis to deter mine factors associated with the response to terlipressin treatment. A univariate analysis showed that DC patients with lower leukocyte count, serum creatinine, INR, total bilirubin (TBIL) and MELD scores, without the occurrence of HE had a good response to terlipressin. The levels of TBIL, INR, serum creatinine and MELD scores were closely related to the patient's grouping, therefore were excluded from multivariate analysis. Among the parameters for multivariate analysis including patient's grouping (DC or ACLF), HE, and leukocyte count, patient' s grouping (DC or ACLF) was independently associated with treatment response. Patients with ACLFAKI were the poorest responders of terlipressin treatment (Table 3 ).
Outcomes
Survival rates at 90 d were significantly decreased in patients with AKI in comparison with those without. Patients with ACLFAKI had the lowest survival rates among all groups (P < 0.001) (Figure 3) . A total of 14 patients received liver transplantation. One of the fourteen patients had AKI before transplantation and this patient survived until a 90 d followup. Five patients (2 patients with DC and 3 patients with ACLF) were lost to followup. All patients with mild CHB survived at 90 d followup.
To further assess the effects of AKI, ACLF and DC on 90day mortality, several factors (age, presence of ascites, HE, SBP, and leukocyte count) that were associated with mortality in the univariate analysis were adjusted in a Cox proportional hazards model (Table  4) . ACLFAKI patients had a highest death risk [HR 7.986 (3.82316.683)], markedly higher than that in 
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DISCUSSION
This study was conducted to explore the etiology, natural course and prognostic differences of AKI between patients with HBVACLF and HBVDC. The response to terlipressin was also assessed between the two groups. We have demonstrated that the structural tubular damage is the dominant pathophysiological mechanism of AKI during the course of ACLFAKI. We have also showed that AKI in HBVACLF patients were more progressive and have a lower response rate to terlipressin treatment as well as a worse prognosis compared with that in HBVDC patients.
To the best of our knowledge, there is only one published study by Maiwall et al [16] that reported differences in AKI between ACLF and DC patients. In that study, patients with ACLFAKI were found to be more likely to have structural kidney injury, which had a greater possibility to resolve despite of the faster progression and poorer prognosis compared to patients with DC. However, the majority of patients in that study were caused by alcoholic cirrhosis and AKI were classified based on microscopic urinalysis [16] , which cannot accurately distinguish the type of renal injury in some cases [17, 18] . Current study is the first one to investigate differences in AKI between HBVACLF and HBVDC patients by evaluating of the levels of novel tubular damage biomarkers and comparing the patients' response to terlipressin treatment in different groups.
Accumulating evidences has shown that biomarkers of renal tubular injury in urine can distinguish between structural and functional renal impairment, though the specific biomarkers for differential diagnosis and their effect size remain controversial [7, 8] . Fagundes et al [10] have previously shown that NGAL levels in urine could distinguish structural and functional kidney injury effectively. Ariza et al [19] also found that urinary NGAL is a good biomarker for differential diagnosis, followed by IL18, but CysC and KIM1 were found less useful for this purpose. Belcher et al [7] studied five biomarkers (NGAL, IL18, LFABP, KIM1 and albumin) in their research and concluded that a combination of all those biomarkers significantly improved accuracy in the differentiation of structural and functional kidney injury compared with any single biomarker alone.
In the current study, five of the most extensively studied biomarkers (NGAL, CysC, LFABP, IL18, and KIM1) were evaluated. Four (NGAL, CysC, LFABP, and IL18) of these biomarkers levels in urine were markedly elevated in ACLFAKI patients, but not in DCAKI patients and those without AKI. According to the findings of previous studies, the results of current study drove us to the hypothesis that AKI in HBVACLF patients is more likely to be caused by structural kidney injury than in HBVDC patients, and our findings are consistent with that of Maiwall et al [16] . In addition to Maiwall's findings, we have further revealed that AKI is not only more progressive in HBVACLF patients but also associated with poor recovery.
In patients with DC, organ hypoperfusion due to progressive hemodynamic dysfunction caused by serious splanchnic vasodilation is considered a major cause of AKI. Patients with AKI usually have a lower mean arterial pressure (MAP) [2, 20] . Similarly, we found that MAP was significantly lower in the DC-AKI group than in patients without AKI. There was no significant difference in MAP levels between the ACLFAKI and DCAKI groups, which was expected because of the similar but severe hemodynamic changes in ACLF and DC [20, 21] . Previous studies have reported that the systemic inflammatory response plays a more important role than hemodynamic dysfunction in the pathogenesis of ACLF and organ failure, and these patients usually have elevated levels of pathogen associated molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs) [20, 21] . These inflammatory mediators can directly or indirectly lead to microcirculation dysfunction, oxidative stress, mitochondrial energy metabolism disorders, and eventually renal tubular cell apoptosis and necrosis [22, 23] . IL18 is not only a biomarker of kidney injury but also an inflammatory mediator, and the levels of IL-18 in urine were significantly higher in patients with ACLFAKI in this study. We also found significantly higher leukocyte counts in patients with ACLF, especially in those with ACLFAKI. The different pathogeneses of ACLF and DC may explained the hypothesis that there is a difference in the etiology and natural course of AKI between these two disease states. In addition, previous studies have found that hyperbilirubinemia is one of the causes of structural renal injury in patients with liver disease [24, 25] . The level of serum bilirubin in patients with ACLF was significantly higher than that in DC patients, this may also contribute to the differences in AKI between these two diseases.
Terlipressin is a vasoactive agent and has been widely used for the treatment of HRS [11, 26] . Several previous studies have demonstrated that the use of terlipressin significantly improves renal function and survival in patients with decompensated cirrhosis [11, 26] . However, research on the use of terlipressin to treat AKI in ACLF patients is limited. Jindal et al [27] reported that only 35% of patients with ACLFAKI responded to terlipressin, which is lower than 40%60% responders in DCAKI as reported by other investigators. In this study, we also found that the response rate of the ACLF-AKI group was significantly lower than that of the DCAKI group, and having HBVrelated ACLF was an independent predictor of poor response to terlipressin. As terlipressin is ineffective in patients with structural renal impairment, and our study found that the levels of biomarkers that represent structural renal impairment in patients with ACLFAKI was significantly higher than that in patients with DCAKI, we considered the low response rate of terlipressin treatment in ACLF AKI patients is associated with a higher proportion of structural kidney damage in these patients. In addition, previous studies have shown that high serum bilirubin levels are associated with a low response to terlipressin treatment, and elevated serum bilirubin levels are associated with the development of structural kidney injury [24, 25, 28, 29] . Serum bilirubin levels were significantly higher in patients with ACLFAKI than in DCAKI patients in this study, further explaining our results. Although some of patients recieved octreotide, there was no significant difference in the proportion of patients receiving octreotide between the two groups.
There is persuasive evidence that AKI is associated with high mortality in patients with liver disease [30, 31] . Similarly, we also found that survival rates were significantly lower in patients with AKI than those without. Moreover, it is interesting that survival rates in the ACLF AKI group were significantly lower than those in the DC-AKI group. Many studies had demonstrated that the mortality of patients with AKI is stagedependent and closely related to the etiologies of AKI [1, 32, 33] . Singer et al [34] reported that patients with structural kidney injury were usually associated with poor prognosis. Nadim et al [35] also showed that the presence of structural kidney injury was associated with higher mortality. A higher proportion of stage 2 or 3 AKI in HBVACLF patients was observed in this current study and which is more likely to be caused by structural kidney injury. This may explain the lower survival rates in ACLFAKI pateints.
Although this is a prospective observational study with a large series of patients, there are still limitations. First, our findings cannot be further verified,as it is impractical to obtain kidney biopsies from most of the AKI patients in this serious condition. In addition, all patients in our study were enrolled from a single center in China,there may be a certain selection bias. A multicenter prospective study needed for further investigation. Finally, this sutdy mainly focuses on HBV related ACLF and DC patients. One should consider the definitions and etiology differences when interpret these results into western patients , where alcoholism constitutes the major etiology of ACLF (type A non cirrhosis, type B with compensated cirrhosis, type C with decompensated cirrhosis) and DC [4] .
In conclusion, this study demonstrated that AKI in patients with HBVACLF is distinctly different from that in HBVDC patients. In patients with HBVACLF, AKI was more likely to be due to structural kidney injury, tended to be more progressive, with a lower response rate to terlipressin therapy and a poorer prognosis compared with those in DCAKI patients. Accurate differentiating the causes of AKI is critical, and AKI in patients with HBVACLF or HBVDC should be managed in different ways. Further studies are required to validate these findings.
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Research background
Acute kidney injury (AKI) is a common and serious complication of acuteon-chronic liver failure (ACLF) and decompensated cirrhosis (DC). Previous studies have been clearly established that the acute-on-chronic liver failure and decompensated liver cirrhosis are two different diseases.However, the differences in acute kidney injury among patients with these two diseases are Figure 3 Kaplan-Meier curves shows the cumulative survival rates of acute-on-chronic liver failure and decompensated cirrhosis patients categorized accorrding to the presence of acute kidney injury. Survival estimates were compared by log-rank test, P < 0.05 was considered statistically significant. ACLF: Acute-on-chronic liver failure; DC: Decompensated cirrhosis; AKI: Acute kidney injury.
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